{
    "ticker": "DLAKY",
    "name": "Daiichi Sankyo Company, Limited",
    "description": "Daiichi Sankyo Company, Limited is a global pharmaceutical company based in Japan, dedicated to the research, development, and commercialization of innovative medicines. Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Daiichi Sankyo has a rich history that dates back to 1899. With a focus on addressing unmet medical needs, the company has made significant advancements in oncology, cardiovascular, and vaccine development. Daiichi Sankyo is renowned for its flagship product, the cancer treatment agent, Enhertu, which has shown remarkable efficacy in treating various types of breast and gastric cancers. The company is also actively involved in developing novel therapies that leverage its expertise in drug discovery and development, including antibody-drug conjugates and small molecules. In addition to its robust pipeline, Daiichi Sankyo is committed to global health initiatives, aiming to enhance access to health care and improve patient outcomes worldwide. The company\u2019s mission is to contribute to society by creating innovative pharmaceuticals that improve the quality of life for patients and their families.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Tokyo, Japan",
    "founded": "2005",
    "website": "https://www.daiichisankyo.com",
    "ceo": "Seigo Izumo",
    "social_media": {
        "twitter": "https://twitter.com/DaiichiSankyo",
        "linkedin": "https://www.linkedin.com/company/daiichi-sankyo"
    },
    "investor_relations": "https://www.daiichisankyo.com/investors/",
    "key_executives": [
        {
            "name": "Seigo Izumo",
            "position": "CEO"
        },
        {
            "name": "Hiroshi Iwasaki",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "Enhertu",
                "Victoza"
            ]
        },
        {
            "category": "Cardiovascular",
            "products": [
                "Olmesartan",
                "Amlodipine"
            ]
        },
        {
            "category": "Vaccines",
            "products": [
                "Flu Vaccine"
            ]
        }
    ],
    "seo": {
        "meta_title": "Daiichi Sankyo Company, Limited | Innovative Pharmaceuticals",
        "meta_description": "Learn about Daiichi Sankyo, a global leader in pharmaceuticals focused on oncology, cardiovascular treatments, and vaccines, dedicated to improving patient outcomes.",
        "keywords": [
            "Daiichi Sankyo",
            "Pharmaceuticals",
            "Oncology",
            "Cardiovascular",
            "Innovative Medicines"
        ]
    },
    "faq": [
        {
            "question": "What is Daiichi Sankyo known for?",
            "answer": "Daiichi Sankyo is known for its innovative cancer treatments and cardiovascular medications."
        },
        {
            "question": "Who is the CEO of Daiichi Sankyo?",
            "answer": "Seigo Izumo is the CEO of Daiichi Sankyo Company, Limited."
        },
        {
            "question": "Where is Daiichi Sankyo headquartered?",
            "answer": "Daiichi Sankyo is headquartered in Tokyo, Japan."
        },
        {
            "question": "What are Daiichi Sankyo's main products?",
            "answer": "Daiichi Sankyo's main products include Enhertu for oncology and various cardiovascular medications."
        },
        {
            "question": "When was Daiichi Sankyo founded?",
            "answer": "Daiichi Sankyo was founded in 2005."
        }
    ],
    "competitors": [
        "PFE",
        "JNJ",
        "MRK",
        "BMY"
    ],
    "related_stocks": [
        "ABBV",
        "AMGN",
        "GILD",
        "REGN"
    ]
}